Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Genetix Biotherapeutics at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Genetix Biotherapeutics brings 1 presentation to ASH 2026 in New Orleans, and exhibits at Booth 3653. Its program centres on gene therapy for sickle cell disease. It hosts a session linking clinical outcomes to the patient journey and supports a symposium on new sickle cell options.

OrganizationASH 2026 Attendance
Biotech
Privately held company with FDA-approved gene therapies for sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy.
Booth
Exhibiting at Booth 3653
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond
Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them.
Red cells · Cell & gene

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Genetix Biotherapeutics

Tell us what you sell and we’ll find the people at Genetix Biotherapeutics most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction